Literature DB >> 31596449

Risk of Pulmonary Embolism More Than 6 Weeks After Surgery Among Cancer-Free Middle-aged Patients.

Alexandre Caron1, Nicolas Depas1, Emmanuel Chazard1, Cécile Yelnik2, Emmanuelle Jeanpierre3, Camille Paris4, Jean-Baptiste Beuscart1, Grégoire Ficheur1.   

Abstract

Importance: The risk of postoperative pulmonary embolism has been reported to be highest during the first 5 weeks after surgery. However, how long the excess risk of postoperative pulmonary embolism persists remains unknown. Objective: To assess the duration and magnitude of the late postoperative risk of pulmonary embolism among cancer-free middle-aged patients by the type of surgery. Design, Setting, and Participants: Case-crossover analysis to compute the respective risks of pulmonary embolism after 6 types of surgery using data from a French national inpatient database, which covers a total of 203 million inpatient stays over an 8-year period between 2007 and 2014. Participants were cancer-free middle-aged adult patients (aged 45 to 64) with a diagnosis of a first pulmonary embolism. Exposures: Hospital admission for surgery. Surgical procedures were classified into 6 types: (1) vascular surgery, (2) gynecological surgery, (3) gastrointestinal surgery, (4) hip or knee replacement, (5) fractures, and (6) other orthopedic operations. Main Outcomes and Measures: Diagnosis of a first pulmonary embolism.
Results: A total of 60 703 patients were included (35 766 [58.9%] male; mean [SD] age, 56.6 [6.0] years). The risk of postoperative pulmonary embolism was elevated for at least 12 weeks after all types of surgery and was highest during the immediate postoperative period (1 to 6 weeks). The excess risk of postoperative pulmonary embolism ranged from odds ratio (OR), 5.24 (95% CI, 3.91-7.01) for vascular surgery to OR, 8.34 (95% CI, 6.07-11.45) for surgery for fractures. The risk remained elevated from 7 to 12 weeks, with the OR ranging from 2.26 (95% CI, 1.81-2.82) for gastrointestinal operations to 4.23 (95% CI, 3.01-5.92) for surgery for fractures. The risk was not clinically significant beyond 18 weeks postsurgery for all types of procedures. Conclusions and Relevance: The risk of postoperative pulmonary embolism is elevated beyond 6 weeks postsurgery regardless of the type of procedure. The persistence of this excess risk suggests that further randomized clinical trials are required to evaluate whether the duration of postoperative prophylactic anticoagulation should be extended and to define the optimal duration of treatment with regard to both the thrombotic and bleeding risks.

Entities:  

Mesh:

Year:  2019        PMID: 31596449      PMCID: PMC6802263          DOI: 10.1001/jamasurg.2019.3742

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  33 in total

1.  Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study.

Authors:  V V Kakkar; J L Balibrea; J Martínez-González; Paolo Prandoni
Journal:  J Thromb Haemost       Date:  2010-04-30       Impact factor: 5.824

2.  Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Elie A Akl; Mark Crowther; David D Gutterman; Holger J Schuünemann
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  A comparison of the empirical performance of methods for a risk identification system.

Authors:  Patrick B Ryan; Paul E Stang; J Marc Overhage; Marc A Suchard; Abraham G Hartzema; William DuMouchel; Christian G Reich; Martijn J Schuemie; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

4.  Extended versus conventional thromboprophylaxis after major abdominal and pelvic surgery: Systematic review and meta-analysis of randomized clinical trials.

Authors:  Emanuele Rausa; Michael E Kelly; Emanuele Asti; Alberto Aiolfi; Gianluca Bonitta; Desmond C Winter; Luigi Bonavina
Journal:  Surgery       Date:  2018-09-03       Impact factor: 3.982

5.  Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis.

Authors:  Claudio Cimminiello; Paolo Prandoni; Giancarlo Agnelli; Giovanni Di Minno; Hernan Polo Friz; Francesco Scaglione; Patrizia Boracchi; Giuseppe Marano; Job Harenberg
Journal:  Intern Emerg Med       Date:  2017-07-29       Impact factor: 3.397

6.  Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

Authors:  Michael Rud Lassen; Alexander Gallus; Gary E Raskob; Graham Pineo; Dalei Chen; Luz Margarita Ramirez
Journal:  N Engl J Med       Date:  2010-12-23       Impact factor: 91.245

7.  Risk of gastrointestinal bleeding in patients undergoing total hip or knee replacement compared with matched controls: a nationwide cohort study.

Authors:  Arief Lalmohamed; Peter Vestergaard; M Kassim Javaid; Anthonius de Boer; Hubertus G M Leufkens; Tjeerd P van Staa; Frank de Vries
Journal:  Am J Gastroenterol       Date:  2013-04-30       Impact factor: 10.864

8.  Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom.

Authors:  Consuelo Huerta; Saga Johansson; Mari-Ann Wallander; Luis A García Rodríguez
Journal:  Arch Intern Med       Date:  2007-05-14

9.  Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study.

Authors:  Siân Sweetland; Jane Green; Bette Liu; Amy Berrington de González; Marianne Canonico; Gillian Reeves; Valerie Beral
Journal:  BMJ       Date:  2009-12-03

Review 10.  Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.

Authors:  Rachel Forster; Marlene Stewart
Journal:  Cochrane Database Syst Rev       Date:  2016-03-30
View more
  3 in total

1.  The Safety and Efficacy of Apixaban (Eliquis) in 5017 Post-bariatric Patients with 95.3% Follow-up: a Multicenter Study.

Authors:  Amit Surve; James Potts; Daniel Cottam; Mitchell Roslin; Walter Medlin; Miro Uchal; Christina Richards; Legrand Belnap
Journal:  Obes Surg       Date:  2022-04-27       Impact factor: 3.479

2.  Predictors of venous thromboembolism in COVID-19 patients: results of the COVID-19 Brazilian Registry.

Authors:  Warley Cezar da Silveira; Lucas Emanuel Ferreira Ramos; Rafael Tavares Silva; Bruno Barbosa Miranda de Paiva; Polianna Delfino Pereira; Alexandre Vargas Schwarzbold; Andresa Fontoura Garbini; Bruna Schettino Morato Barreira; Bruno Mateus de Castro; Carolina Marques Ramos; Caroline Danubia Gomes; Christiane Corrêa Rodrigues Cimini; Elayne Crestani Pereira; Eliane Würdig Roesch; Emanuele Marianne Souza Kroger; Felipe Ferraz Martins Graça Aranha; Fernando Anschau; Fernando Antonio Botoni; Fernando Graça Aranha; Gabriela Petry Crestani; Giovanna Grunewald Vietta; Gisele Alsina Nader Bastos; Jamille Hemétrio Salles Martins Costa; Jéssica Rayane Corrêa Silva da Fonseca; Karen Brasil Ruschel; Leonardo Seixas de Oliveira; Lílian Santos Pinheiro; Liliane Souto Pacheco; Luciana Borges Segala; Luciana Siuves Ferreira Couto; Luciane Kopittke; Maiara Anschau Floriani; Majlla Magalhães Silva; Marcelo Carneiro; Maria Angélica Pires Ferreira; Maria Auxiliadora Parreiras Martins; Marina Neves Zerbini de Faria; Matheus Carvalho Alves Nogueira; Milton Henriques Guimarães Júnior; Natália da Cunha Severino Sampaio; Neimy Ramos de Oliveira; Nicole de Moraes Pertile; Pedro Guido Soares Andrade; Pedro Ledic Assaf; Reginaldo Aparecido Valacio; Rochele Mosmann Menezes; Saionara Cristina Francisco; Silvana Mangeon Meirelles Guimarães; Silvia Ferreira Araújo; Suely Meireles Rezende; Susany Anastácia Pereira; Tatiana Kurtz; Tatiani Oliveira Fereguetti; Carísi Anne Polanczyk; Magda Carvalho Pires; Marcos André Gonçalves; Milena Soriano Marcolino
Journal:  Intern Emerg Med       Date:  2022-06-01       Impact factor: 5.472

3.  Venous thromboembolism after lower extremity orthopedic surgery: A population-based nationwide cohort study.

Authors:  Inger Lise Gade; Søren Kold; Marianne T Severinsen; Kristian H Kragholm; Christian Torp-Pedersen; Søren R Kristensen; Signe J Riddersholm
Journal:  Res Pract Thromb Haemost       Date:  2020-11-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.